These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Levine AS; Sivulich M; Wiernik PH; Levy HB Cancer Res; 1979 May; 39(5):1645-50. PubMed ID: 371793 [No Abstract] [Full Text] [Related]
27. Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys. Stephen EL; Hilmas DE; Mangiafico JA; Levy HB Science; 1977 Sep; 197(4310):1289-90. PubMed ID: 408923 [TBL] [Abstract][Full Text] [Related]
28. Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Houston WE; Crabbs CL; Stephen EL; Levy HB Infect Immun; 1976 Jul; 14(1):318-9. PubMed ID: 820645 [TBL] [Abstract][Full Text] [Related]
29. Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice. Olsen GA; Kern ER; Overall JC J Infect Dis; 1978 Apr; 137(4):428-36. PubMed ID: 206632 [TBL] [Abstract][Full Text] [Related]
30. Interferon response to poly IC/poly-L-lysine in normal and lymphocyte-suppressed primates. DeWitt CM; Field AK J Interferon Res; 1984; 4(1):1-8. PubMed ID: 6201567 [TBL] [Abstract][Full Text] [Related]
31. Hyporeactivity to interferon induction in newborn piglets. Derbyshire JB; Lesnick CE J Interferon Res; 1990 Feb; 10(1):47-53. PubMed ID: 1691769 [TBL] [Abstract][Full Text] [Related]
32. Immune response modifying activity in mice of polyinosinic: polycytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly-ICLC]. Chirigos MA; Papademetriou V; Bartocci A; Read E; Levy HB Int J Immunopharmacol; 1981; 3(4):329-37. PubMed ID: 7333719 [TBL] [Abstract][Full Text] [Related]
33. [Interferon production by various means of administering modified poly I-C]. Andzhaparidze OG; Bektemirov TA; Burgasova MP; Ogleznev KIa Vopr Virusol; 1981; (4):407-10. PubMed ID: 6171096 [TBL] [Abstract][Full Text] [Related]
34. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. Hawkins MJ; Levin M; Borden EC J Biol Response Mod; 1985 Dec; 4(6):664-8. PubMed ID: 2418164 [TBL] [Abstract][Full Text] [Related]
35. The effect of interferon induction in newborn piglets on the humoral immune response to oral vaccination with transmissible gastroenteritis virus. Derbyshire JB; Lesnick CE Vet Immunol Immunopathol; 1990 Mar; 24(3):227-34. PubMed ID: 1692649 [TBL] [Abstract][Full Text] [Related]
36. Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. Levy HB; Lvovsky E J Infect Dis; 1978 Jan; 137(1):78-81. PubMed ID: 624854 [TBL] [Abstract][Full Text] [Related]
37. Comparative activities of selected combinations of acyclovir, vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice. Crane LR; Milne DA; Sunstrum JC; Lerner AM Antimicrob Agents Chemother; 1984 Oct; 26(4):557-62. PubMed ID: 6083754 [TBL] [Abstract][Full Text] [Related]
38. Dose and regimen effects of poly ICLC, an interferon inducer, in a multi-dose bleomycin model of interstitial pulmonary fibrosis. Wild JS; Hyde DM; Giri SN Pharmacol Toxicol; 1994 Jul; 75(1):42-8. PubMed ID: 7526360 [TBL] [Abstract][Full Text] [Related]
39. Potentiation of the cytocidal effect of human immune interferon by different synthetic double-stranded RNAs in the refractory human colon carcinoma cell line BE. Chapekar MS; Glazer RI Cancer Res; 1986 Apr; 46(4 Pt 1):1698-702. PubMed ID: 3081254 [TBL] [Abstract][Full Text] [Related]